Paul Laland

Vice President, Corporate Communications at Principia Biopharma, Inc.

Paul Laland

Paul Laland

Vice President, Corporate Communications at Principia Biopharma, Inc.

Overview
RelSci Relationships

343

Number of Boards

1

Contact Data
Trying to get in touch with Paul Laland? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Paul Laland likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chief Business Officer at Aravive, Inc.

Relationship likelihood: Strong

Senior Vice President, Head of Research at Principia Biopharma, Inc.

Relationship likelihood: Average

Benefit Plan Administrator at Principia Biopharma, Inc.

Relationship likelihood: Average

Chief Business Officer at Principia Biopharma, Inc.

Relationship likelihood: Average

Chief Scientific Officer at Principia Biopharma, Inc.

Relationship likelihood: Average

Chairman at Ascenta Therapeutics, Inc.

Relationship likelihood: Average

Chief Financial Officer & Chief Accounting Officer at Sutro Biopharma, Inc.

Relationship likelihood: Average

Chief Financial Officer & Chief Accounting Officer at Principia Biopharma, Inc.

Relationship likelihood: Average

President & Chief Executive Officer at Ilypsa, Inc.

Relationship likelihood: Average

Senior Vice President, Regulatory Affairs at Catalyst Biosciences, Inc.

Relationship likelihood: Average

Paths to Paul Laland
Potential Connections via
Relationship Science
You
Paul Laland
Vice President, Corporate Communications at Principia Biopharma, Inc.
Career History
Vice President, Corporate Communications
Current

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

Vice President-Corporate Communications
Prior - 2009

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA.

Managing Director
Prior

WeissComm Partners, Inc. provides public relations and corporate communication services. It offers messaging and positioning, communications strategy, corporate communication, investor relation, product communication, media relation, issues and crisis management, professional and advocacy relation, and regulatory communication services, as well as clinical trial services. The company serves the healthcare, consumer products and technology markets. WeisComm Partners was founded in 2001 and is headquartered in San Francisco, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Paul Laland. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Paul Laland's profile does not indicate a business or promotional relationship of any kind between RelSci and Paul Laland.